Retatrutide Delivers 28.7% Weight Loss in Phase 3 � The Most Potent Obesity Peptide Yet

Eli Lilly has reported landmark Phase 3 data for retatrutide, its investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The TRIUMPH-4 trial, conducted in adults with obesity and knee osteoarthritis, showed participants on the 12mg weekly dose lost an average of 71.2 pounds � representing 28.7% of baseline body weight over 68 weeks. This surpasses tirzepatide's 22.5% and semaglutide's 15% from comparable trials.

The mechanism behind retatrutide's superior efficacy lies in its three-receptor approach. GLP-1 agonism reduces appetite and slows gastric emptying; GIP agonism enhances insulin sensitivity and complements GLP-1 effects; glucagon receptor activation directly increases energy expenditure and promotes fat oxidation. This multi-pathway assault on adiposity produces weight loss that no single-receptor compound can match.

Beyond weight, the TRIUMPH-4 trial also demonstrated substantial osteoarthritis pain relief � a 75% reduction in pain scores on retatrutide compared to 40% in the placebo group. This suggests that retatrutide's benefits extend meaningfully beyond scale weight, reducing the mechanical and inflammatory burden on joints. Seven additional Phase 3 readouts are expected in 2026, including a type 2 diabetes trial that already showed A1C reductions of up to 2.0%.

Lilly plans to file an NDA in Q4 2026. If approved, retatrutide would likely become the most potent obesity drug available, though the complete safety profile � including emerging signals around gastrointestinal tolerability � will be closely scrutinized during the regulatory review process.